Literature DB >> 29929189

Dexmedetomidine Protects Neural Stem Cells from Ketamine-Induced Injury.

Pan Lu1, Shan Lei1, Weisong Li1, Yang Lu1, Juan Zheng1, Ning Wang1, Yongjun Xia1,2, Haixia Lu3, Xinlin Chen3, Yong Liu3, Peng-Bo Zhang1.   

Abstract

BACKGROUND/AIMS: Ketamine inhibits the proliferation of neural stem cells (NSCs) and disturbs normal neurogenesis. Dexmedetomidine provides neuroprotection against volatile anesthetic-induced neuroapoptosis and cognitive impairment in the developing brain. Whether it may protect NSCs from ketamine-induced injury remains unknown. In this study, we investigated the protective effects of dexmedetomidine on ketamine-exposed NSCs and explored the mechanisms potentially involved.
METHODS: Primary NSC cultures were characterized using immunofluorescence. Cell viability was determined using a Cell Counting Kit 8 assay. Proliferation and apoptosis were assessed with BrdU incorporation and TUNEL assays, respectively. Protein levels of cleaved caspase-3, phosphorylated protein kinase B (p-Akt), and glycogen synthase kinase-3β (p-GSK-3β) were quantified using western blotting.
RESULTS: Ket-amine significantly decreased NSC viability and proliferation and increased their apoptosis. Dexmedetomidine increased NSC proliferation and decreased their apoptosis in a dose-dependent manner. Furthermore, dexmedetomidine pretreatment notably augmented the viability and proliferation of ketamine-exposed NSCs and reduced their apoptosis. Moreover, dexmedetomidine lessened caspase-3 activation and increased p-Akt and p-GSK-3β levels in NSCs exposed to ketamine. The protective effects of dexmedetomidine on ketamine-exposed NSCs could be partly reversed by the PI3K inhibitor LY294002.
CONCLUSIONS: Collectively, these findings indicate that dexmedetomidine may protect NSCs from ketamine-induced injury via the PI3K/Akt/GSK-3β signaling pathway.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Dexmedetomidine; Ketamine; Neural stem cells; Neurotoxicity; PI3K/Akt/GSK-3β pathway

Mesh:

Substances:

Year:  2018        PMID: 29929189     DOI: 10.1159/000490823

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  3 in total

1.  General anaesthesia during infancy reduces white matter micro-organisation in developing rhesus monkeys.

Authors:  Jeffrey T Young; Roza M Vlasova; Brittany R Howell; Rebecca C Knickmeyer; Elyse Morin; Kaela I Kuitchoua; Gabriele R Lubach; Jean Noel; Xiaoping Hu; Yundi Shi; Gibson Caudill; Andrew L Alexander; Marc Niethammer; Merle G Paule; Christopher L Coe; Mar Sanchez; Martin Styner
Journal:  Br J Anaesth       Date:  2021-02-03       Impact factor: 11.719

2.  Effect of supplemental dexmedetomidine in interventional embolism on cerebral oxygen metabolism in patients with intracranial aneurysms.

Authors:  Zhang Guo; Weiwei Wang; Dahua Xie; Ruisheng Lin
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

3.  Dexmedetomidine protects PC12 cells from ropivacaine injury through miR-381/LRRC4 /SDF-1/CXCR4 signaling pathway.

Authors:  Ying Xue; Tao Xu; Wei Jiang
Journal:  Regen Ther       Date:  2020-05-21       Impact factor: 3.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.